MiraVista Diagnostics
MiraVista Diagnostics is a family-owned, Indianapolis-based clinical reference laboratory specializing in diagnostic testing for serious fungal infections, serving hospitals, university medical centers, and reference laboratories across North America with a proprietary menu of antigen, antibody, and PCR assays.
- Company typePrivate
- Founded2002
- HeadquartersIndianapolis, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What MiraVista Diagnostics does
MiraVista Diagnostics is a privately held, family-owned clinical reference laboratory founded in 2002 by Dr. Lawrence Joseph Wheat, MD, a pioneering infectious disease scientist. The company operates an exclusive focus on diagnostic testing for serious fungal infections, processing more than 100,000 tests annually at its Indianapolis, Indiana facility. MiraVista serves hospitals, university medical centers, and large reference laboratories across the United States and Canada, with a separate veterinary diagnostics channel through MiraVistaVets.com contributing approximately one-quarter of testing volume.
The company's product portfolio spans three diagnostic methodologies: antigen detection (proprietary MVista® and MycoMEIA® EIA assays for Histoplasma, Blastomyces, Coccidioides, Aspergillus, Cryptococcus, and Beta-D Glucan), antibody detection (immunodiffusion and IgG/IgM EIAs), and molecular detection (including the MVista® Pulmonary Fungal Pathogen PCR Panel detecting four fungal pathogens on BAL specimens). The lab is CAP + CLIA certified for clinical testing and ISO 13485 certified for in vitro diagnostic kit manufacturing and distribution, enabling a vertically integrated model of clinical services plus IVD kit commercialization. The R&D team has authored 1,000+ peer-reviewed publications and is currently developing rapid lateral flow point-of-care devices for coccidioidomycosis and other endemic mycoses.
MiraVista generates revenue primarily through usage-based clinical diagnostic testing services (specimens received from healthcare facilities and processed at the Indianapolis reference lab), with a secondary revenue stream from IVD kit manufacturing and distribution. The go-to-market model is direct sales to enterprise healthcare buyers, supplemented by active participation in infectious disease and clinical microbiology conferences (IDWeek, ASM Microbe, MSGERC, SCACM, CHEST, ATS, ISHLT). Operational hours are extended to evenings and Saturdays for high-volume antigen tests, and infectious disease specialists are available for clinical consultation. The company has no external institutional equity investment, has not been the subject of M&A activity, and is funded through operating cash flow, federal SBIR grants (notably a $582,312 NIAID Phase I grant in 2017), and Indiana state economic development incentives.
MiraVista Diagnostics firmographics
Firmographics- Name
- MiraVista Diagnostics
- Legal name
- MiraVista Diagnostics LLC
- Website
- https://miravistalabs.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MiraVista Diagnostics is a family-owned, Indianapolis-based clinical reference laboratory specializing in diagnostic testing for serious fungal infections, serving hospitals, university medical centers, and reference laboratories across North America with a proprietary menu of antigen, antibody, and PCR assays.
- Ownership category
- akta.pro rank
MiraVista Diagnostics industry classification
Industry- Product category
- Clinical Diagnostic Laboratory Services
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD)
- akta.pro secondary industry
- Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)
Keywords
Where MiraVista Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Indianapolis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MiraVista Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Clinical Diagnostic Testing Services: MiraVista processes over 100,000 diagnostic tests per year at its onsite CLIA accredited clinical laboratory. Testing covers antigen detection (Histoplasma, Blastomyces, Coccidioides, Aspergillus, Cryptococcus, Beta-D Glucan), antibody detection, and molecular PCR detection for serious fungal pathogens. Samples are received from reference labs, academic medical centers, and hospitals throughout the US and Canada.
- In Vitro Diagnostic (IVD) Kit Manufacturing and Distribution: MiraVista is ISO 13485 certified to design, manufacture and distribute in vitro diagnostic test kits for fungal diseases. The company is developing lateral flow devices (similar to home pregnancy tests) for rapid detection of fungal infections including coccidioidomycosis.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
MiraVista Diagnostics product offering
Product offeringCore offering
MiraVista Diagnostics operates an onsite CAP + CLIA certified clinical reference laboratory that develops, manufactures, and processes diagnostic tests for serious fungal infections including aspergillosis, blastomycosis, coccidioidomycosis (Valley Fever), cryptococcosis, histoplasmosis, and Pneumocystis. The company offers a comprehensive menu of antigen detection (proprietary MycoMEIA® and MVista® EIA tests), antibody detection (immunodiffusion and EIA formats), and molecular PCR diagnostic tests, processing over 100,000 specimens per year from hospitals, university medical centers, and reference laboratories. MiraVista is also ISO 13485 certified to design, manufacture, and distribute in vitro diagnostic (IVD) test kits for fungal diseases and operates a veterinary diagnostics line through MiraVistaVets.com.
Product overview
MiraVista Diagnostics operates as a clinical reference laboratory offering a comprehensive menu of fungal infection diagnostic tests organized across three main methodologies: antigen detection tests (including the proprietary MycoMEIA® and MVista® branded EIA assays), antibody detection tests (immunodiffusion and EIA formats), and molecular detection tests (including the MVista® Pulmonary Fungal Pathogen PCR Panel). The company processes over 100,000 diagnostic tests annually and holds ISO 13485 certification for designing, manufacturing, and distributing in vitro diagnostic test kits for fungal diseases. The product portfolio includes tests for Aspergillus, Blastomyces, Coccidioides, Cryptococcus, Histoplasma, and Pneumocystis organisms.
Differentiator
Problem solved
Functional benefit
Brands
- MiraVistaVets.com: Veterinary diagnostic testing division offering fungal infection tests for animal patients.
- MVista
Products and services
- Fungal Infection Clinical Reference Laboratory Testing Service Comprehensive clinical reference laboratory service processing over 100,000 specimens per year for serious fungal infections (histoplasmosis, blastomycosis, coccidioidomycosis, aspergillosis, cryptococcosis, Pneumocystis). Serves hospitals, university medical centers, and large reference laboratories across the U.S. and Canada. Includes direct access to infectious disease specialists for clinical consultation.
- MVista® Pulmonary Fungal Pathogen PCR Panel A multiplex PCR molecular diagnostic assay that detects DNA from four fungal pathogens (Histoplasma spp., Blastomyces spp., Coccidioides spp., Pneumocystis jirovecii) on BAL specimens with 1-2 business day turnaround, providing speciation and simultaneous detection capability.
- MycoMEIA® Aspergillus Galf Urine EIA A urine-based antigen assay exclusive to MiraVista that complements serum galactomannan testing to improve diagnostic confidence for invasive aspergillosis (IA), useful when serum results are negative or evolving, particularly early in disease.
- Quantitative Antigen Detection Test Menu (Histoplasma, Blastomyces, Coccidioides, Aspergillus, Cryptococcus, Beta-D Glucan) A suite of proprietary quantitative enzyme immunoassays and latex agglutination tests for antigen detection of six major fungal pathogens (Histoplasma, Blastomyces, Coccidioides, Aspergillus, Cryptococcus) plus Beta-D Glucan pan-fungal marker. Used for diagnosis and treatment monitoring of invasive fungal infections.
- Antibody Detection Test Menu (Immunodiffusion and EIA Tests) A suite of immunodiffusion and enzyme immunoassays for serological antibody detection of Aspergillus, Blastomyces, Coccidioides, and Histoplasma to support diagnosis of fungal infections, particularly acute pulmonary infections.
- Veterinary Fungal Diagnostic Testing Service (MiraVistaVets.com) Veterinary diagnostic testing service for fungal infections in animal patients, distributed through the dedicated MiraVistaVets.com portal. Targets veterinary practices and represents approximately 25% of company testing volume.
- In Vitro Diagnostic (IVD) Kit Manufacturing and Distribution ISO 13485 certified manufacturing and distribution of in vitro diagnostic (IVD) test kits for fungal diseases, including lateral flow rapid detection devices in development for coccidioidomycosis and other endemic mycoses.
- Pneumocystis DNA PCR Test DNA-based PCR test for detection of Pneumocystis jirovecii from patient specimens, used for diagnosis of Pneumocystis pneumonia in immunocompromised patients.
Quantifiable outcome
- MiraVista processes over 100,000 fungal diagnostic tests annually
- +3 more outcomes
Companies that use MiraVista Diagnostics
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
MiraVista Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
MiraVista Diagnostics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor.
- Indiana Procurement Technical Assistance Center (PTAC)minorIndiana PTAC provided counseling and application assistance to help MiraVista secure the federal SBIR grant and government contract opportunities.
- Inside Indiana Business / Life Sciences IndianaminorInside Indiana Business featured MiraVista Diagnostics in its Life Sciences Indiana publication, providing media coverage and visibility for the company's research initiatives and expansion plans.
Scale indicators6 records
Recent moves7 records
Expansion highlights13 records
MiraVista Diagnostics competitors and assessment
Company assessmentDirect peers
- ARUP Laboratories: ARUP is a nonprofit clinical reference laboratory affiliated with the University of Utah that offers a broad esoteric testing menu including fungal diagnostics, serving hospitals and reference labs nationally. Directly comparable as a high-complexity reference lab serving similar hospital/academic medical center customers with esoteric infectious disease testing.
- Viracor Eurofins Clinical Diagnostics: Viracor Eurofins is a specialty reference lab focused on immunology, infectious disease, and transplant diagnostics, including fungal PCR and antigen testing. Directly comparable as a specialty esoteric lab competing for hospital and transplant center send-out fungal testing volume.
- Mayo Clinic Laboratories: Mayo Clinic Laboratories is the reference testing arm of Mayo Clinic, offering a comprehensive esoteric menu including fungal serology, antigen, and molecular assays, and serving hospitals, clinics, and reference labs globally. Comparable in serving the same hospital/reference lab customer base for high-complexity fungal diagnostics, though as a generalist esoteric lab rather than a fungal-focused specialist.
- IMMY (Immune-Mycologics): IMMY is a privately held diagnostics company based in Oklahoma specializing in fungal disease diagnostics, manufacturing IVD kits (including Cryptococcal antigen lateral flow and Histoplasma tests). Direct peer in fungal IVD manufacturing and clinical testing with overlapping customers in endemic mycology diagnostics.
- Associates of Cape Cod (ACC): Associates of Cape Cod is a specialty manufacturer of fungal endotoxin and (1,3)-β-D-glucan detection products used in clinical and industrial microbiology. Overlaps with MiraVista in fungal diagnostics with complementary focus on LAL/beta-D-glucan products and clinical laboratory customers.
Broad incumbents
- Quest Diagnostics: Quest Diagnostics is one of the largest clinical reference laboratories in the US, offering a broad menu including infectious disease and mycology testing. Overlaps with MiraVista in clinical diagnostic testing services to hospitals and reference labs, but as a generalist lab rather than a fungal-specialized provider.
- Laboratory Corporation of America (Labcorp): Labcorp is a leading global clinical laboratory network offering comprehensive diagnostic testing including fungal cultures, serology, and molecular assays. Competes in the same reference lab space for fungal diagnostic send-out volume, but with a much broader non-specialized menu.
- Bio-Rad Laboratories: Bio-Rad is a global clinical diagnostics and life science research company offering a broad infectious disease and quality control product portfolio including fungal testing reagents. Overlaps with MiraVista in IVD kit manufacturing and clinical lab customers, but as a diversified life sciences tools and diagnostics incumbent.
Regional players
- Bruker (Microbiology / MALDI Biotyper): Bruker offers MALDI Biotyper and molecular diagnostic platforms for fungal identification in clinical microbiology labs, primarily used in Europe and globally. Adjacent in fungal diagnostics, serving clinical microbiology customers with culture-based organism ID rather than antigen/antibody/PCR send-out testing.
Others
- Galderma (β-D-glucan clinical diagnostic assets via affiliates): Not a direct lab peer but relevant in the broader fungal diagnostics ecosystem as global pharmaceutical/diagnostic companies that have historically held or distributed fungal antigen testing products. Listed to reflect the broader competitive set MiraVista may face as larger diagnostic players enter or expand in mycology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
MiraVista Diagnostics social profiles
Digital presenceMiraVista Diagnostics compliance and trust
Trust signalCompliance3 records
MiraVista Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
MiraVista Diagnostics leadership team
Management profileNumber of profiles
Profiles2 records
MiraVista Diagnostics subsidiaries and ownership
Company hierarchySubsidiaries1 record
MiraVista Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MiraVista Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MiraVista Diagnostics
What does MiraVista Diagnostics do?
MiraVista Diagnostics operates an onsite CAP + CLIA certified clinical reference laboratory that develops, manufactures, and processes diagnostic tests for serious fungal infections including aspergillosis, blastomycosis, coccidioidomycosis (Valley Fever), cryptococcosis, histoplasmosis, and Pneumocystis. The company offers a comprehensive menu of antigen detection (proprietary MycoMEIA® and MVista® EIA tests), antibody detection (immunodiffusion and EIA formats), and molecular PCR diagnostic tests, processing over 100,000 specimens per year from hospitals, university medical centers, and reference laboratories. MiraVista is also ISO 13485 certified to design, manufacture, and distribute in vitro diagnostic (IVD) test kits for fungal diseases and operates a veterinary diagnostics line through MiraVistaVets.com.
Is MiraVista Diagnostics a public or private company?
MiraVista Diagnostics is a private company. It is classified as family owned and is currently operating.
When was MiraVista Diagnostics founded?
MiraVista Diagnostics was founded in 2002. It employs 11 to 50 people.
Where is MiraVista Diagnostics based?
MiraVista Diagnostics is headquartered in Indianapolis, United States, in the North America region.
How does MiraVista Diagnostics make money?
Two revenue lines are on record. Clinical Diagnostic Testing Services are the primary driver. The others are in Vitro Diagnostic (IVD) Kit Manufacturing and Distribution.
Who are MiraVista Diagnostics's main competitors?
Direct peers on record are ARUP Laboratories, Viracor Eurofins Clinical Diagnostics, Mayo Clinic Laboratories, IMMY (Immune-Mycologics) and Associates of Cape Cod (ACC). Broad incumbents are Quest Diagnostics, Laboratory Corporation of America (Labcorp) and Bio-Rad Laboratories. Bruker (Microbiology / MALDI Biotyper) is listed as a regional player. Galderma (β-D-glucan clinical diagnostic assets via affiliates) is listed as an others.
Does MiraVista Diagnostics have an API?
No public API is recorded for MiraVista Diagnostics.
What industry is MiraVista Diagnostics in?
MiraVista Diagnostics's product category is Clinical Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAFAMAD, Microbiology & Infectious Disease Testing Laboratories, with a secondary code of HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST). Its NAICS code is 621511 and its SIC code is 8071.